As the majority of the population ages, the instances of these people acquiring glaucoma also go up. This is in part because of the lifestyle that they lead, and through genetic composition. Sadly, a substantial portion of these people are not aware that they carry the disease until it’s too late. The detection of this disease early on is something that Aerie Pharmaceuticals is working. The business is continually developing methods of detection and cure for this eye disease.
The company is registered as a clinical-stage pharmaceutical business with Rhopressa as its lead product candidate. Currently, the product is on its third state of clinical study. It completed its Phase 2 just last May 2013.